Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies
Philipp Haselmayer(Merck KGaA, Darmstadt (Germany)), Hong Ji(Merck Serono (Switzerland))
Cited by 38
Related Papers
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
|The Journal of Immunology|2019|145